Clinical Trial Detail

NCT ID NCT02231164
Title LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Boehringer Ingelheim
Indications

lung adenocarcinoma

Therapies

Docetaxel

Nintedanib

Age Groups: adult

Additional content available in CKB BOOST